592 related articles for article (PubMed ID: 9806559)
1. Timing of onset of contraceptive effectiveness in Depo-Provera users. II. Effects on ovarian function.
Petta CA; Faúndes A; Dunson TR; Ramos M; DeLucio M; Faúndes D; Bahamondes L
Fertil Steril; 1998 Nov; 70(5):817-20. PubMed ID: 9806559
[TBL] [Abstract][Full Text] [Related]
2. Timing of onset of contraceptive effectiveness in Depo-Provera users: Part I. Changes in cervical mucus.
Petta CA; Faundes A; Dunson TR; Ramos M; DeLucio M; Faundes D; Bahamondes L
Fertil Steril; 1998 Feb; 69(2):252-7. PubMed ID: 9496338
[TBL] [Abstract][Full Text] [Related]
3. Delayed first injection of the once-a-month injectable contraceptive containing 25 mg of medroxyprogesterone acetate and 5 mg of E(2)-cypionate: effects on ovarian function.
Petta CA; Hays M; Brache V; Massai R; Hua Y; Alvarez-Sánchez F; Croxatto H; d'Arcangues C; Cook LA; Bahamondes L
Fertil Steril; 2001 Apr; 75(4):744-8. PubMed ID: 11287029
[TBL] [Abstract][Full Text] [Related]
4. Once-a-month estrogen/progestogen injectables.
D'arcangues C
Entre Nous Cph Den; 1991 Dec; (19):15. PubMed ID: 12222332
[TBL] [Abstract][Full Text] [Related]
5. Effects of a sequential regimen of mifepristone-medroxyprogesterone acetate on ovarian function, endometrial development and hormonal parameters.
Croxatto HB; Massai MR; Salvatierra AM; Fuentealba B; Croxatto HD; Lähteenmäki P
Contraception; 1996 Aug; 54(2):79-86. PubMed ID: 8842583
[TBL] [Abstract][Full Text] [Related]
6. Effect of depo-medroxyprogesterone acetate on serum progesterone levels when administered on various cycle days.
Siriwongse T; Snidvongs W; Tantayaporn P; Leepipatpaiboon S
Contraception; 1982 Nov; 26(5):487-93. PubMed ID: 6218964
[TBL] [Abstract][Full Text] [Related]
7. Metabolic parameter, bleeding, and weight changes in U.S. women using progestin only contraceptives.
Mainwaring R; Hales HA; Stevenson K; Hatasaka HH; Poulson AM; Jones KP; Peterson CM
Contraception; 1995 Mar; 51(3):149-53. PubMed ID: 7621683
[TBL] [Abstract][Full Text] [Related]
8. Forearm bone density in users of Depo-Provera as a contraceptive method.
Bahamondes L; Perrotti M; Castro S; Faúndes D; Petta C; Bedone A
Fertil Steril; 1999 May; 71(5):849-52. PubMed ID: 10231044
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic study of different doses of Depo Provera.
Fotherby K; Koetsawang S; Mathrubutham M
Contraception; 1980 Nov; 22(5):527-36. PubMed ID: 6451351
[TBL] [Abstract][Full Text] [Related]
10. Effect of pretreatment counseling on discontinuation rates in Chinese women given depo-medroxyprogesterone acetate for contraception.
Lei ZW; Wu SC; Garceau RJ; Jiang S; Yang QZ; Wang WL; Vander Meulen TC
Contraception; 1996 Jun; 53(6):357-61. PubMed ID: 8773423
[TBL] [Abstract][Full Text] [Related]
11. Depo Provera. Position paper on clinical use, effectiveness and side effects.
Bigrigg A; Evans M; Gbolade B; Newton J; Pollard L; Szarewski A; Thomas C; Walling M
Br J Fam Plann; 1999 Jul; 25(2):69-76. PubMed ID: 10454658
[TBL] [Abstract][Full Text] [Related]
12. Long-term depot medroxyprogesterone acetate (Depo-Provera) use in inner-city adolescents.
Polaneczky M; Liblanc M
J Adolesc Health; 1998 Aug; 23(2):81-8. PubMed ID: 9714170
[TBL] [Abstract][Full Text] [Related]
13. Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension): assessment of return of ovulation after three monthly injections in surgically sterile women.
Rahimy MH; Ryan KK
Contraception; 1999 Oct; 60(4):189-200. PubMed ID: 10640165
[TBL] [Abstract][Full Text] [Related]
14. Suppression of ovarian function with the transdermally given synthetic progestin ST 1435.
Laurikka-Routti M; Haukkamaa M; Lähteenmäki P
Fertil Steril; 1992 Oct; 58(4):680-4. PubMed ID: 1426309
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of Cyclofem in the treatment of depot medroxyprogesterone acetate induced amenorrhea.
Piya-Anant M; Koetsawang S; Patrasupapong N; Dinchuen P; d'Arcangues C; Piaggio G; Pinol A
Contraception; 1998 Jan; 57(1):23-8. PubMed ID: 9554247
[TBL] [Abstract][Full Text] [Related]
16. Depo Provera: still controversial.
Wren LM
Int Health News; 1988 Feb; 9(2):2-3, 8. PubMed ID: 12179873
[TBL] [Abstract][Full Text] [Related]
17. Clinical evaluation of the therapeutic effectiveness of ethinyl oestradiol and oestrone sulphate on prolonged bleeding in women using depot medroxyprogesterone acetate for contraception. World Health Organization, Special Programme of Research, Development and Research Training in Human Reproduction, Task Force on Long-acting Systemic Agents for Fertility Regulation.
Said S; Sadek W; Rocca M; Koetsawang S; Kirwat O; Piya-Anant M; Dusitsin N; Sethavanich S; Affandi B; Hadisaputra W; Kazi A; Ramos RM; d'Arcangues C; Belsey EM; Noonan E; Olayinka I; Pinol A
Hum Reprod; 1996 Oct; 11 Suppl 2():1-13. PubMed ID: 8982739
[TBL] [Abstract][Full Text] [Related]
18. Sequential regimen of the antiprogesterone RU486 and synthetic progestin for contraception.
Kekkonen R; Lähteenmäki P; Luukkainen T; Tuominen J
Fertil Steril; 1993 Oct; 60(4):610-5. PubMed ID: 8405512
[TBL] [Abstract][Full Text] [Related]
19. Bone density in long term users of depot medroxyprogesterone acetate.
Gbolade B; Ellis S; Murby B; Randall S; Kirkman R
Br J Obstet Gynaecol; 1998 Jul; 105(7):790-4. PubMed ID: 9692421
[TBL] [Abstract][Full Text] [Related]
20. Bone density among long-term users of medroxyprogesterone acetate as a contraceptive.
Paiva LC; Pinto-Neto AM; Faundes A
Contraception; 1998 Dec; 58(6):351-5. PubMed ID: 10095971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
